Bayer AG (ETR: BAYN) reported its third‑quarter 2026 financial results, with group sales of €10.053 billion, up 4.1 % year‑on‑year (+1.9 % currency‑ and portfolio‑adjusted), as the Pharmaceuticals Division reached what the company described as a turning point in its growth trajectory, powered by Nubeqa (darolutamide) and Kerendia (finerenone).
Q3 2026 Earnings Snapshot
| Item | Detail |
|---|---|
| Company | Bayer AG (ETR: BAYN) |
| Reporting Period | Third quarter 2026 |
| Group Sales | €10.053 billion, +4.1 % YoY (+1.9 % currency‑ and portfolio‑adjusted) |
| Pharmaceuticals Division Sales | €4.680 billion, +8 % YoY (+6.4 % currency‑ and portfolio‑adjusted) |
| Growth Leaders | Nubeqa (oncology) and Kerendia (chronic kidney disease & heart failure) |
| Announcement Date | 3 Nov 2026 |
Pharmaceuticals Division – Growth Drivers
- Nubeqa (darolutamide): Sales grew 58.3 % (currency‑ and portfolio‑adjusted), with the oncology treatment reaching approximately €1 billion in Q3 sales alone.
- Kerendia (finerenone): Sales rose 64.9 % (currency‑ and portfolio‑adjusted); the chronic kidney disease and heart failure therapy surpassed €1 billion in sales over the 12‑month period since 1 October 2025.
- Beyonttra (acoramidis): Sales for the cardiomyopathy product grew to five times the prior‑year level, primarily driven by significant volume expansion following its successful European launch.
- Radiology: The business also delivered a strong performance during the quarter (specific figures not disclosed).
Legacy Product Erosion – Patent Expirations
| Product | Indication | Sales Trend (Currency‑ & Portfolio‑Adjusted) | Notes |
|---|---|---|---|
| Xarelto (rivaroxaban) | Oral anticoagulant | −30.7 % | Decline aligned with expectations; rate gradually narrowing |
| Eylea (aflibercept) | Ophthalmology | −23.5 % | Decline aligned with expectations; rate gradually narrowing |
| Eylea 8 mg | Extended‑interval formulation | – | Already accounts for approximately 60 % of total Eylea sales |
Both declines stem from patent expirations and are proceeding in line with company expectations, with erosion rates for each product narrowing over time.
Market Impact & Outlook
- Division Turning Point: The Pharmaceuticals Division’s return to growth — +8 % YoY, outpacing group sales — signals that the Nubeqa–Kerendia engine is now offsetting loss‑of‑exclusivity drag faster than the market may have anticipated.
- Billion‑Euro Franchise Depth: With Nubeqa at ~€1 billion per quarter and Kerendia crossing €1 billion on a rolling 12‑month basis, Bayer now fields two blockbuster growth assets alongside the rapidly scaling Beyonttra.
- Lifecycle Management: The Eylea 8 mg transition — already ~60 % of Eylea sales — demonstrates effective extended‑interval formulation defense amid generic erosion of the original product.
- Investor Takeaway: The combination of narrowing legacy declines and accelerating new‑product momentum strengthens the case for sustained Pharmaceuticals recovery heading into 2027.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Bayer AG’s sales trends, product performance, and business outlook. Actual results may differ materially due to risks including currency fluctuations, competitive dynamics, patent‑expiration impacts, regulatory developments, and market adoption of new products.-Fineline Info & Tech
